SA521422728B1 - مثبطات فوسفوينوسيتيد 3- كيناز الموضعية - Google Patents

مثبطات فوسفوينوسيتيد 3- كيناز الموضعية

Info

Publication number
SA521422728B1
SA521422728B1 SA521422728A SA521422728A SA521422728B1 SA 521422728 B1 SA521422728 B1 SA 521422728B1 SA 521422728 A SA521422728 A SA 521422728A SA 521422728 A SA521422728 A SA 521422728A SA 521422728 B1 SA521422728 B1 SA 521422728B1
Authority
SA
Saudi Arabia
Prior art keywords
acid
compound
formula
models
weight
Prior art date
Application number
SA521422728A
Other languages
Arabic (ar)
English (en)
Inventor
اف. عبدالمجيد أحمد.
كيدونيوس اجيس
روسي توماسي
اس. تان هوك
Original Assignee
فينـثيرا، إنك.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by فينـثيرا، إنك. filed Critical فينـثيرا، إنك.
Publication of SA521422728B1 publication Critical patent/SA521422728B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SA521422728A 2019-02-06 2021-08-05 مثبطات فوسفوينوسيتيد 3- كيناز الموضعية SA521422728B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962802093P 2019-02-06 2019-02-06
US202062958049P 2020-01-07 2020-01-07

Publications (1)

Publication Number Publication Date
SA521422728B1 true SA521422728B1 (ar) 2023-12-26

Family

ID=71835949

Family Applications (2)

Application Number Title Priority Date Filing Date
SA521422728A SA521422728B1 (ar) 2019-02-06 2021-08-05 مثبطات فوسفوينوسيتيد 3- كيناز الموضعية
SA522441650A SA522441650B1 (ar) 2019-02-06 2021-08-05 مثبطات فوسفوينوسيتيد 3-كيناز الموضعية

Family Applications After (1)

Application Number Title Priority Date Filing Date
SA522441650A SA522441650B1 (ar) 2019-02-06 2021-08-05 مثبطات فوسفوينوسيتيد 3-كيناز الموضعية

Country Status (14)

Country Link
US (2) US11661429B2 (cg-RX-API-DMAC7.html)
EP (1) EP3920911A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022519317A (cg-RX-API-DMAC7.html)
KR (1) KR20210124310A (cg-RX-API-DMAC7.html)
CN (1) CN114072144A (cg-RX-API-DMAC7.html)
AU (1) AU2020219065A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021015353A2 (cg-RX-API-DMAC7.html)
IL (1) IL285020B2 (cg-RX-API-DMAC7.html)
MA (1) MA54907A (cg-RX-API-DMAC7.html)
MX (1) MX2021009142A (cg-RX-API-DMAC7.html)
SA (2) SA521422728B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108274SA (cg-RX-API-DMAC7.html)
TW (1) TWI862548B (cg-RX-API-DMAC7.html)
WO (1) WO2020163525A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108274SA (en) 2019-02-06 2021-08-30 Venthera Inc Topical phosphoinositide 3-kinase inhibitors
EP4192431A1 (en) * 2020-08-04 2023-06-14 Venthera, Inc. Formulations of phosphoinositide 3-kinase inhibitors
EP4401732A4 (en) * 2021-09-15 2025-09-24 Dermbiont Inc COMPOSITIONS AND FORMULATIONS FOR TOPICAL USE OF AN AKT INHIBITOR FOR THE PREVENTION, TREATMENT, AND AMELIORATION OF SKIN DISEASES, CONDITIONS, AND DISORDERS
CN115991716B (zh) * 2021-10-19 2025-10-17 中国药科大学 嘧啶并环类化合物及其衍生物、制备方法、药物组合物和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
JP3602519B2 (ja) 2002-07-12 2004-12-15 コナミ株式会社 ビデオゲーム装置、画像処理方法及びプログラム
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
WO2007021933A2 (en) 2005-08-12 2007-02-22 The General Hospital Corporation Methods and compositions for use in treating vascular diseases and conditions
US8129371B2 (en) * 2007-10-16 2012-03-06 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
AU2008335156A1 (en) * 2007-12-10 2009-06-18 Metaproteomics, Llc Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith
AU2008363813A1 (en) * 2008-11-07 2010-05-14 Children's Hospital Medical Center Fusogenic properties of saposin C and related proteins and peptides for application to transmembrane drug delivery systems
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
PT2385832E (pt) 2009-01-08 2015-11-02 Curis Inc Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
EP2510121A1 (en) 2009-12-11 2012-10-17 Wyeth LLC Phosphatidylinositol-3-kinase pathway biomarkers
CN102268014B (zh) 2010-06-03 2015-06-03 上海艾力斯医药科技有限公司 一类稠合杂芳基衍生物、制备方法及其应用
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
BR112013008615B1 (pt) 2010-10-13 2021-05-11 Medivir Ab composição farmacêutica
CN104010494B (zh) 2011-07-28 2017-07-04 霍夫曼-拉罗奇有限公司 Pik3ca h1047r敲入非人动物乳腺癌模型
US8871781B2 (en) 2011-11-30 2014-10-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating a subject for a lymphatic malformation
CN104379163A (zh) 2012-06-08 2015-02-25 霍夫曼-拉罗奇有限公司 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合
WO2014046617A1 (en) 2012-09-19 2014-03-27 Agency For Science, Technology And Research Compositions and methods for treating cancer
EP3294314A4 (en) 2015-05-15 2019-01-16 Memorial Sloan Kettering Cancer Center USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES
JP7051693B2 (ja) 2016-02-19 2022-04-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル PIK3CA関連過成長症候群(PROS CLOVaS症候群)の処置に使用するためのBYL719(アルペリシブ)
EP3251657A1 (en) 2016-05-30 2017-12-06 Sun Pharmaceutical Industries Limited Topical aqueous spray compositions of halobetasol
ES2893527T3 (es) 2016-12-28 2022-02-09 Hisamitsu Pharmaceutical Co Parche
SG11202108274SA (en) 2019-02-06 2021-08-30 Venthera Inc Topical phosphoinositide 3-kinase inhibitors
EP4192431A1 (en) 2020-08-04 2023-06-14 Venthera, Inc. Formulations of phosphoinositide 3-kinase inhibitors

Also Published As

Publication number Publication date
MA54907A (fr) 2022-05-11
CN114072144A (zh) 2022-02-18
US12522614B2 (en) 2026-01-13
EP3920911A4 (en) 2023-03-08
AU2020219065A1 (en) 2021-09-23
MX2021009142A (es) 2021-10-13
JP2025036464A (ja) 2025-03-14
TWI862548B (zh) 2024-11-21
JP2022519317A (ja) 2022-03-22
KR20210124310A (ko) 2021-10-14
US20230416269A1 (en) 2023-12-28
JP7781250B2 (ja) 2025-12-05
EP3920911A1 (en) 2021-12-15
TW202045513A (zh) 2020-12-16
CA3127686A1 (en) 2020-08-13
SA522441650B1 (ar) 2024-02-29
IL285020B2 (en) 2025-11-01
US11661429B2 (en) 2023-05-30
WO2020163525A1 (en) 2020-08-13
US20200247816A1 (en) 2020-08-06
IL285020B1 (en) 2025-07-01
BR112021015353A2 (pt) 2021-10-05
SG11202108274SA (en) 2021-08-30
IL285020A (en) 2021-09-30

Similar Documents

Publication Publication Date Title
EA202091267A1 (ru) 1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47
MX2023007192A (es) Inhibidores de prmt5.
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
JOP20200315A1 (ar) مركبات بورينون واستخدامها في معالجة السرطان
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
CL2021002681A1 (es) Inhibidores de la dihidroorotato deshidrogenasa.
EA202092086A1 (ru) Ингибиторы аргиназы
CU20210065A7 (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria en cdk2
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
EA201890086A1 (ru) 1,4-замещенные производные пиперидина
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
BR112015032595A2 (pt) inibidores de ido
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
MX2024002391A (es) Inhibidores de indolina de kif18a.
SA522441650B1 (ar) مثبطات فوسفوينوسيتيد 3-كيناز الموضعية
MX2020004981A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
BR112022003584A2 (pt) Compostos de pirrolopirimidina inibidores de perk
MX2022002443A (es) Compuestos inhibidores de perk.
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
EP4706394A3 (en) Use of alkoxypyrazoles as nitrification inhibitors
MX374758B (es) Inhibidores de tirosina cinasa de bruton.
MX2024006684A (es) Inhibidores de hdac novedosos y uso terapéutico de estos.
GEAP202416390A (en) Bicyclic heteroaromatic inhibitors of klk5
MX2023015408A (es) Inhibidores de transglutaminasas.